Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | PHGDH | O43175 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900762 | 0.84 | HCAR1 (0.41) | HCAR1HSD11B1SCN9AOPRM1NR3C2 | |
| SCHEMBL2897642 | 0.81 | HCAR1 (0.38) | HCAR1HSD11B1PHGDHSCN9ATP53 | |
| SCHEMBL2903050 | 0.80 | OPRM1 (0.45) | OPRM1L3MBTL1PKM | |
| SCHEMBL2902919 | 0.79 | HCAR1 (0.36) | HCAR1HSD11B1PHGDHSCN9ANR3C2 | |
| SCHEMBL2902635 | 0.78 | OPRM1 (0.44) | OPRM1L3MBTL1 | |
| SCHEMBL2900638 | 0.73 | HCAR1 (0.35) | HCAR1HSD11B1MAPTL3MBTL1 | |
| SCHEMBL15016086 | 0.71 | MARS1 (0.43) | HCAR1HSD11B1MAPTOPRM1L3MBTL1 | |
| SCHEMBL2347651 | 0.70 | NPC1 (0.42) | MAPTRAB9ASMN1; SMN2OPRM1NOTUM | |
| SCHEMBL9788349 | 0.70 | LMNA (0.47) | HCAR1PHGDHSCN9ATP53MAPT | |
| SCHEMBL1902318 | 0.68 | NPC1 (0.46) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | HCAR1 2640/4885HSD11B1 4143/4885PHGDH 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.